Andrew J. Armstrong
Duke University
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
Prostate Cancer Treatment and Research
Solid evidence · 3 supporting papers · latest 2026
Drug-Induced Adverse Reactions
Solid evidence · 1 supporting paper · latest 2026
Cancer, Lipids, and Metabolism
Solid evidence · 1 supporting paper · latest 2026
Prostate Cancer Diagnosis and Treatment
Solid evidence · 2 supporting papers · latest 2026
Chemotherapy-related skin toxicity
Supporting evidence · 1 supporting paper · latest 2026
Radiopharmaceutical Chemistry and Applications
Supporting evidence · 1 supporting paper · latest 2026
Publications (3)
External validation of the NADIR model for early prostate‐specific antigen response prediction in enzalutamide‐treated metastatic hormone‐sensitive prostate cancer: An analysis of the ARCHES trial
2026DOI
Darolutamide With Concomitant Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer
2026DOI
Successful cabazitaxel desensitization after severe taxane hypersensitivity reactions: a brief report
2026DOI
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Duke University
Source: ScienceWe Extractor · retrieved 2026-09-27